- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00006463
Ecteinascidin 743 in Treating Children With Refractory Solid Tumors
Phase I Study of ET-743 in Pediatric Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Ecteinascidin 743 may be an effective treatment for solid tumors.
PURPOSE: Phase I trial to study the effectiveness of ecteinascidin 743 in treating children who have refractory solid tumors.
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
OBJECTIVES: I. Determine the maximum tolerated dose and dose-limiting toxicity of ecteinascidin 743 in pediatric patients with refractory solid tumors. II. Determine the pharmacokinetics of this drug in these patients. III. Determine the antitumor activity of this drug in this patient population.
OUTLINE: This is a dose escalation, multicenter study. Patients are stratified according to pretreatment (pretreated vs less heavily pretreated). Patients receive ecteinascidin 743 IV over 3 hours on day 1. Treatment continues every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of ecteinascidin 743 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicities.
PROJECTED ACCRUAL: A total of 3-20 patients will be accrued for this study within 2 years.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Victoria
-
Parkville, Victoria, Australien, 3052
- Royal Children's Hospital
-
-
Western Australia
-
Perth, Western Australia, Australien, 6001
- Princess Margaret Hospital for Children
-
-
-
-
Arkansas
-
Little Rock, Arkansas, Förenta staterna, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
La Jolla, California, Förenta staterna, 92093-0658
- University of California San Diego Cancer Center
-
Los Angeles, California, Förenta staterna, 90095-1781
- Jonsson Comprehensive Cancer Center, UCLA
-
Los Angeles, California, Förenta staterna, 91010
- Beckman Research Institute, City of Hope
-
Los Angeles, California, Förenta staterna, 90027-0700
- Children's Hospital Los Angeles
-
Orange, California, Förenta staterna, 92868
- Children's Hospital of Orange County
-
Palo Alto, California, Förenta staterna, 94304
- Lucile Packard Children's Hospital at Stanford
-
San Francisco, California, Förenta staterna, 94115-0128
- UCSF Cancer Center and Cancer Research Institute
-
-
District of Columbia
-
Washington, District of Columbia, Förenta staterna, 20010-2970
- Children's National Medical Center
-
-
Florida
-
Gainesville, Florida, Förenta staterna, 32610-100277
- Shands Hospital and Clinics, University of Florida
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30322
- Emory University Hospital - Atlanta
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60614
- Children's Memorial Hospital, Chicago
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46202-5265
- Indiana University Cancer Center
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21231
- Johns Hopkins Oncology Center
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02115
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Förenta staterna, 02111
- Boston Floating Hospital Infants and Children
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48109
- Mott Children's Hospital
-
Detroit, Michigan, Förenta staterna, 48201
- Children's Hospital of Michigan
-
-
Minnesota
-
Rochester, Minnesota, Förenta staterna, 55905
- Mayo Clinic Cancer Center
-
-
Mississippi
-
Jackson, Mississippi, Förenta staterna, 39216-4505
- University of Mississippi Medical Center
-
-
Missouri
-
Kansas City, Missouri, Förenta staterna, 64108
- Children's Mercy Hospital
-
Saint Louis, Missouri, Förenta staterna, 63104
- Cardinal Glennon Children's Hospital
-
-
New Jersey
-
Hackensack, New Jersey, Förenta staterna, 07601
- Hackensack University Medical Center
-
-
New York
-
Buffalo, New York, Förenta staterna, 14263-0001
- Roswell Park Cancer Institute
-
New York, New York, Förenta staterna, 10021
- Memorial Sloan-Kettering Cancer Center
-
New York, New York, Förenta staterna, 10032
- Columbia Presbyterian Hospital
-
Syracuse, New York, Förenta staterna, 13210
- State University of New York - Upstate Medical University
-
-
North Carolina
-
Durham, North Carolina, Förenta staterna, 27710
- Duke Comprehensive Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45229-3039
- Children's Hospital Medical Center - Cincinnati
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Förenta staterna, 15213
- Children's Hospital of Pittsburgh
-
-
South Carolina
-
Charleston, South Carolina, Förenta staterna, 29425-0721
- Medical University of South Carolina
-
-
Tennessee
-
Memphis, Tennessee, Förenta staterna, 38105-2794
- Saint Jude Children's Research Hospital
-
Nashville, Tennessee, Förenta staterna, 37232-6838
- Vanderbilt Cancer Center
-
-
Texas
-
Fort Worth, Texas, Förenta staterna, 76104
- Cook Children's Medical Center - Fort Worth
-
Houston, Texas, Förenta staterna, 77030
- Baylor College of Medicine
-
Houston, Texas, Förenta staterna, 77030-4009
- University of Texas - MD Anderson Cancer Center
-
San Antonio, Texas, Förenta staterna, 78284-7811
- University of Texas Health Science Center at San Antonio
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84132
- Huntsman Cancer Institute
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98105
- Children's Hospital and Regional Medical Center - Seattle
-
-
Wisconsin
-
Madison, Wisconsin, Förenta staterna, 53792-0001
- University of Wisconsin Hospital and Clinics
-
Milwaukee, Wisconsin, Förenta staterna, 53226
- Midwest Children's Cancer Center
-
-
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Kanada, H3H 1P3
- Montreal Children's Hospital
-
Montreal, Quebec, Kanada, H3T 1C5
- Hopital Sainte Justine
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
DISEASE CHARACTERISTICS: Histologically confirmed malignant solid tumor at original diagnosis Refractory to standard treatment or no curative therapy available No CNS tumor No bone marrow metastases (for less heavily pretreated stratum only)
PATIENT CHARACTERISTICS: Age: At least 365 days to 17 years Performance status: Karnofsky 50-100% (for patients older than 10 years) Lansky 50-100% (for patients 10 years and younger) Life expectancy: At least 8 weeks Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 (transfusion independent) Hemoglobin at least 8.0 g/dL (RBC transfusion allowed) Hepatic: Bilirubin no greater than normal SGPT no greater than 2.5 times normal Albumin at least 2 g/dL Alkaline phosphatase normal Gamma glutamyl transferase less than 2.5 times normal Renal: Creatinine no greater than 1.5 times normal OR Creatinine clearance or GFR at least lower limit of normal Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception Creatine phosphokinase less than 2 times normal No uncontrolled infection Seizure disorder allowed if well controlled on anticonvulsants No CNS toxicity greater than grade II
PRIOR CONCURRENT THERAPY: Biologic therapy: At least 1 week since prior biologic therapy and recovered At least 1 week since prior growth factor therapy At least 6 months since prior peripheral blood stem cell transplantation and no evidence of graft-vs-host disease For less heavily pretreated stratum: No prior peripheral blood stem cell transplantation Chemotherapy: At least 4 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) and recovered No prior ecteinascidin 743 For less heavily pretreated stratum: No more than 2 prior chemotherapy regimens Endocrine therapy: Not specified Radiotherapy: At least 2 weeks since prior local palliative radiotherapy (small port) At least 6 weeks since prior substantial bone marrow radiotherapy At least 6 months since prior craniospinal radiotherapy or radiotherapy to 50% or greater of pelvis For less heavily pretreated stratum: No prior craniospinal irradiation of 18Gy or greater No prior irradiation to greater than 50% of pelvis Recovered from toxic effects of prior radiotherapy Surgery: Not specified Other: No concurrent foods or medication that interferes with P-450 metabolism Anticonvulsants allowed
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Therapy ECTEINASCIDIN 743 (1100 ug/m2 )
|
Andra namn:
|
Experimentell: ECTEINASCIDIN 743 (1300 ug/m2)
|
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Progressionsfri överlevnad
Tidsram: Studiens längd
|
Studiens längd
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Dose Limiting Toxicity
|
To determine the maximum tolerated dose (MTD) of vincristine, when used in combination with irinotecan, and the dose-limiting toxicity (DLT) of this combination; irinotecan will be administered IV over 1 hour x 5 days, q 21 days, with vincristine IVP days 1, 8, 15, 22, 29, every 42 days, to children with refractory solid tumors.
|
|
Determine a safe and tolerable dose of vincristine, when administered with irinotecan
|
To determine a safe and tolerable dose of vincristine, when administered with irinotecan, for future evaluation in phase II clinical trials.
|
|
Determine the pharmacokinetics of vincristine and irinotecan
Tidsram: Length of study
|
To determine the pharmacokinetics of vincristine and irinotecan (and its active metabolite SN-38) when administered in combination to children with refractory cancer.
|
Length of study
|
Determine the incidence and severity of other toxicities
Tidsram: Length of study
|
To determine the incidence and severity of other toxicities of this combination.
|
Length of study
|
Seek preliminary evidence of anti-tumor activity of irinotecan plus vincristine
Tidsram: Length of study
|
To seek preliminary evidence of anti-tumor activity of irinotecan plus vincristine against recurrent solid tumors.
|
Length of study
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Studiestol: Sylvain Baruchel, MD, The Hospital for Sick Children
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- P9972
- COG-P9972 (Annan identifierare: Children's Oncology Group)
- POG-P9972 (Annan identifierare: Pediatric Oncology Group)
- CDR0000068273 (Annan identifierare: Clinical Trials.gov)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på ECTEINASCIDIN 743
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Janssen PharmaceuticalsIndragenMyxoid liposarkom | Steg III mjukdelssarkom AJCC v7 | Steg IV mjukdelssarkom AJCC v7 | Rundcelligt liposarkom | Ooperbar mjukvävnadssarkom | Metastaserande mjukdelssarkomFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)IndragenRefraktär kronisk lymfatisk leukemi | Refraktärt litet lymfocytiskt lymfomFörenta staterna
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); EMD SeronoAvslutadMetastaserande leiomyosarkom | Ooperabelt Leiomyosarkom | Metastaserande liposarkom | Ooperabelt liposarkomFörenta staterna
-
Yale UniversityEdison Pharmaceuticals Inc; Rembrandt FoundationAvslutad
-
Edison Pharmaceuticals IncAvslutad
-
TakedaTakeda Development Center Americas, Inc.Avslutad
-
TakedaRekrytering
-
PTC TherapeuticsAvslutadMitokondriella sjukdomar | Läkemedelsresistent epilepsi | Leighs sjukdom | Leighs syndrom | Mitokondriell encefalopati (MELAS) | Pontocerebellär hypoplasi typ 6 (PCH6) | Alpers sjukdom | Alpers syndromFörenta staterna, Spanien, Storbritannien, Kanada, Frankrike, Italien, Polen, Sverige, Japan
-
TakedaAvslutad
-
ShireAvslutadÄrftligt angioödemFörenta staterna, Kanada, Tyskland, Ungern, Spanien